The conversation covered several issues relating to use and interpretation of non-invasive testing. Two issues addressed use on NITs in diagnostics and, separately, drug development. A third considered how to develop and support end points generated around non-invasive tests instead of biopsy. In the process, the group discussed the shortcomings of biopsy as a gold standard as well as the practical challenges that keep biopsy in its current place in the hierarchy of test options.

TOPICS: cirrhosis, Diagnostic Tests, EASL, EchoSens, Elastography, FDA, FIB-4, FibroScan, Fibrosis Level 3, Fibrosis Level 4, Genfit, MRI-PDFF, NAFLD, NASH, non-invasive liver testing, Nordic Biosciences, Perspectum Diagnostics, population screening, Siemens Healthineers, Testing, TrialDesign, NIS-4, MRE, ELF, Pro-C3, cT(1), ILC2021

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast